Biotechnology
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...
2022-10-11 19:00
1239
Samsung Biologics unlocks additional capacity for production at its newest Plant 4
* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...
2022-10-11 19:00
1402
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...
2022-10-08 10:43
2152
First patient treated in Clarity's therapeutic prostate cancer trial
Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...
2022-10-07 21:06
1782
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...
2022-10-04 19:00
1397
Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry
OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...
2022-10-04 14:00
1131
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
* Two distinctive platforms will streamline the antibody development process. * With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies. * DEVELOPICK™ provides early insight and selection guidance to save time and cost to maxi...
2022-09-29 19:00
1308
NeuShen Therapeutics Closes Pre-A Financing with ~$20M
* Closure of pre-A financing round led by LAMPAM Capital * Dual internal discovery platforms of small molecule and AAV-based gene therapy targeting neurological and psychiatric disorders SHANGHAI, Sept. 29, 2022 /PRNewswire/ -- NeuShen Therapeutics, Inc., a biotechnology company focusing on d...
2022-09-29 17:50
1745
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC
SUZHOU, China, Sept. 29, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide (used to be ...
2022-09-29 14:22
1339
GC Labs becomes the first Korean laboratory to obtain certification of CDC standardization programs (VDSCP & HoSt)
YONGIN, South Korea and AUSTIN, Texas, Sept. 28, 2022 /PRNewswire/ -- GC Labs, a leadingSouth Korea clinical laboratory, today announced that it has recently obtained certification of standardization programs from the U.S. Centers for Disease Control and Prevention (CDC) for vitamin D and hormone...
2022-09-29 08:17
1187
First-Ever Spinal Surgical Hand-held Robot by Point Robotics MedTech to Make Its Worldwide Debut in the United States
TAIPEI, Sept. 28, 2022 /PRNewswire/ -- Point Robotics MedTech Inc. (Point Robotics), a rising star in the field of orthopedic surgery, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its minimally invasive surgical robot, POINT™ Kinguide Robotic-Assisted Surgical Sy...
2022-09-28 21:01
995
Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
* Rising from last year's ranking, the company's united effort and dedication to integrating sustainable practices in all areas of its business drew recognition from EcoVadis, which provided high marks in responsible procurement and environmental management. * More than 100,000 companies from...
2022-09-28 19:00
1321
Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfolio companies progressed greatly. ABM Therapeutics Annou...
2022-09-28 18:31
1778
The 6th China (Shenzhen) Innovation & Entrepreneurship International Competition Eindhoven, Netherlands Division is Open for Registration
DIGITAL ACCESS TO THE WORLD CREATES A BETTER FUTURE EINDHOVEN, Netherlands, Sept. 28, 2022 /PRNewswire/ -- China （Shenzhen）Innovation and Entrepreneurship Competition, known as the "Olympics" of innovation and entrepreneurship circle, is here again! The sixth International competition was offici...
2022-09-28 17:55
1258
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
2022-09-27 21:40
1415
Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies
NANJING and HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy, today announced that a phase I clinical study results of RD13-01, an anti-CD7 universal CAR-T therapy product, h...
2022-09-26 21:00
1648
PharmAbcine to Participate in BIO-Europe 2022
DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place ...
2022-09-26 20:00
1350
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) o...
2022-09-26 20:00
1638
CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy
HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric An...
2022-09-26 12:31
1465
Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential
SUZHOU, China and ROCKVILLE, Md., Sept. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the results from a Phase I and Phase II study of ...
2022-09-21 22:49
1571
Week's Top Stories
Most Reposted
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
[Picked up by 313 media titles]
2024-10-25 18:29
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
[Picked up by 300 media titles]
2024-10-25 22:48
2024 Malaysia E-commerce Product Selection Expo Reaches Major Milestone Attracting Leading Brands and Businesses From China
[Picked up by 300 media titles]
2024-10-25 07:00
RuggON Showcases Latest Mining Technology at IMARC 2024
[Picked up by 296 media titles]
2024-10-28 14:32
TotalEnergies ENEOS Completes a 1.8 MWp Floating Solar Photovoltaic System Project, a Second Collaboration with S. Kijchai Enterprise in Thailand
[Picked up by 288 media titles]
2024-10-29 11:24
Most Read
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
2024-10-25 18:29
8610
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
2024-10-25 22:48
7462
Infobip and Singtel Partner to Advance Customer Engagement for Singapore Businesses with Rich Communication Services
2024-10-25 12:30
7039
Global development relies on cooperation
2024-10-25 12:38
6056
Peak Energy CEO Gavin Adda Speaks at Asia Clean Energy Summit 2024
2024-10-25 18:30
5759
